Down 25% in 2021, Is Compass Pathways Undervalued?

·4-min read
Down 25% in 2021, Is Compass Pathways Undervalued?

To help people suffering from depression and other mental illnesses, Compass Pathways (NASDAQ: CMPS) makes psychedelic therapies based on chemicals like psilocybin. While its interventions may never be as widely used as the first-line depression treatments of today like cognitive behavioral therapy (CBT), they just might offer a source of hope. Compass' shares are down by more than 25% from the start of the year, and there's no guarantee that they'll recover.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting